Uri Aharon - RedHill Biopharma Insider

RedHill Biopharma Ltd -- USA Stock  

USD 0.97  0.00  0.00%

Chief Accounting Officer

Mr. Uri Hananel Aharon serves as Chief Accounting Officer at Redhill Biopharma Ltd, effective since 2012. His work experience includes the following roles Team Manager at Ernst Young Israel and Accounting Intern at Ziv Haft, BDO . He holds a Bachelors degree in Accounting and Economics from The Hebrew University of Jerusalem and a MBA degree, majoring in Business Taxation, from the College of Management Academic Studies, Rishon LeZion.
Age: 35  Executive Since 2011  MBA    
972 3 541 3131  http://www.redhillbio.com
Aharon is a graduate of the Hebrew University and the Academic College for Management, Rishon Lezion .

Management Efficiency

The company has return on total asset (ROA) of (29.24) % which means that it has lost $29.24 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (21.0) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 969.85 K in total debt with debt to equity ratio (D/E) of 0.06 which may suggest the company is not taking enough advantage from borrowing. RedHill Biopharma Ltd has Current Ratio of 5.72 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

RedHill Biopharma Ltd., a biopharmaceutical company, primarily focuses on the development and commercialization of late clinicalstage, proprietary, orallyadministered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. RedHill Biopharma Ltd (REDIF) is traded on OTC Market in USA. It is located in Tel Aviv, and employs 12 people.

Did you try this?

Run Technical Analysis Now
   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
Hide  View All  Next  Launch Technical Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add RedHill Biopharma Ltd to your portfolio

Top Management

RedHill Biopharma Leadership Team
Patricia Anderson, President
Micha Chorin, CFO
Ofer Tsimchi, Director
Patrick Mclean, Executive
Aida Bibliowicz, President, MBA
Ori Shilo, CEO, MBA
Shmuel Cabilly, Director
Dror BenAsher, Chairman
Kenneth Reed, Director, Ph.D
Elkan Gamzu, Executive, Ph.D
Alicia Rotbard, Director
Adi Frish, SVP
Guy Goldberg, Executive
Reza Fathi, SVP, Ph.D
Tom Lang, President
Clara Fehrmann, Executive
Pascal Weerts, Director
Eric Swenden, Director
Dan Suesskind, Director
Gilead Raday, President
Rick Scruggs, Director
Terry Plasse, Director
Danielle Abramson, Director
Uri Aharon, Executive, MBA
Aliza Rotbard, Director
Shani Maurice, President
Patricia Bandeira, Executive, MBA
Ira Kalfus, Director, Ph.D
Nurit Benjamini, Director, MBA

Stock Performance

RedHill Biopharma Performance Indicators